Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Pharm. 2019 Jun 14;16(7):2872–2883. doi: 10.1021/acs.molpharmaceut.8b01343

Figure 5. Anti-metastatic efficacy of ALN-m/DTX in syngeneic 4T1 breast cancer bone metastasis model.

Figure 5.

Treatment consisted of iv injections of PBS, DTX (in Tween 80/ethanol/PEG300), ALK-m/DTX, or ALN-m/DTX at an equivalent dose of 10 mg DTX/kg. Arrows represent iv injections. (A) Quantification of bone metastasis burden based on whole body BLI imaging; (B) Body weight; (C) Kaplan−Meier survival plot; (D) Histopathological analysis of representative kidney, liver, and spleen of mice received different treatments. Data presented as mean ± SEM (n = 8). *p < 0.05 by log-rank (Mantel-Cox) test.